The Latest
Exkivity Approved for EGFR Exon 20 Insertion+ NSCLC
Drug Therapy for Borderline Personality Disorder Evaluated
Noncompliance to Apixaban for A-Fib Due to Many Factors
Brukinsa Gets Accelerated Approval for Marginal Zone Lymphoma
Linzagolix NDA Submitted for Uterine Fibroid Treatment
FDA Extends Review Period for Nefecon, an Investigational IgA Nephropathy Therapy
Study Evaluating Ampreloxetine for Neurogenic Orthostatic Hypotension Misses Endpoint
FDA Clears VNS Device for Paroxysmal Hemicrania, Hemicrania Continua
COVID-19 Vaccine Effectiveness Changing With Delta Predominance
MPR ARTICLES
